Zobrazeno 21 - 30
of 221
pro vyhledávání: ''
Autor:
Jörn C. Albring, Christoph Schliemann, Matthias Stelljes, Christoph Groth, Patrick Stelmach, Christian Reicherts, Wolfgang E. Berdel, Georg Lenz, Klaus Wethmar, Jan-Henrik Mikesch, Daniela V. Wenge
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e724-e733
Background Blinatumomab and inotuzumab ozogamicin are now widely used to treat relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Patients and Methods We have reported the clinical course of 34 adult patients with r/r B-ALL recei
Autor:
Meletios A. Dimopoulos, Kari Remes, Joana Parreira, Pamela Bacon, Eleni Tholouli, Bjorn Andreasson, Gianpietro Semenzato, Gerard Crotty, Elisabeth Kueenburg, Christian Berthou, Miguel T. Hernandez, Monique C. Minnema, Sarah Peters, Antonia Di Micco, B. Rosettani, Igor Wolfgang Blau, Roman Hájek, Jo Caers, Barbara Gamberi
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia
Clinical Lymphoma, Myeloma & Leukemia, Elsevier, 2020, 20 (10), pp.e629-e644. ⟨10.1016/j.clml.2020.05.006⟩
Clinical Lymphoma, Myeloma & Leukemia, Elsevier, 2020, 20 (10), pp.e629-e644. ⟨10.1016/j.clml.2020.05.006⟩
Introduction Lenalidomide plus dexamethasone is effective and well tolerated in relapsed/refractory multiple myeloma (RRMM). In this observational, noninterventional European post-authorization safety study, the safety profile of lenalidomide plus de
Autor:
Moussab Damlaj, Mohammad Snnallah, Ayman Alhejazi, Bader Alahmari, Mohsen Alzahrani, Razan Bashir, Hind Salama, Ahmed Alaskar, Inaam Shehab Eddine
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:690-696
Background Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with cytarabine and methotrexate (hyper-CVAD) is a commonly used regimen in adults with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (
Autor:
Matthew Ho, Shuhui Deng, Zhen Yu, Yan Xu, Zengjun Li, Gang An, Kenneth C. Anderson, Yu-Tzu Tai, Tengteng Yu, Lugui Qiu, Dehui Zou, Mu Hao
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e652-e659
Background Primary plasma cell leukemia (PPCL) is a rare and aggressive plasma cell disorder. The use of novel agents, together with autologous stem cell transplantation, has improved survival outcome in PPCL. However, the prognosis is still very poo
Mini-Hyper-CVD Combinations for Older Adults: Results of Recent Trials and a Glimpse into the Future
Autor:
Marlise R. Luskin, Daniel J. DeAngelo
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S44-S47
Autor:
R J Ma, Jianmin Guo, Zhongwen Liu, Xiangli Chen, L Jiang, Jie Shi, X L Yuan, Jing Yang, Zunmin Zhu, Yin Zhang, Xiaojian Zhu, Yuzhu Zang, Pingchong Lei, Shiwei Yang, Lin Zhang
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e382-e391
Introduction The purpose of this study was to explore the outcomes of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) plus idarubicin (IDA) as a frontline treatment in adult patients with acute promyelocytic leukemia (APL). Patients and Met
Autor:
Robert M. Dean, Muhammad Junaid Tariq, Faiz Anwer, Aqsa Ashraf, Malik Qistas Ahmed, Talha Bin Farooq, Arafat Ali Farooqui, Muhammad Salman Faisal, Shaha Nabeel, Abraham S. Kanate, Ahmad Anjum, Saif Ur Rehman, Arshia Akbar
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e414-e426
Chronic lymphocytic leukemia (CLL) typically affects older patients; administration of traditional cytotoxic therapies in old patients has very modest benefit with no survival improvement. With better understanding of CLL biology, trends are shifting
Autor:
Aaron S. Rosenberg, Brian A. Jonas, Mehrdad Abedi, Julian R Davis, Rasmus T. Hoeg, Joseph Tuscano
Publikováno v:
Clin Lymphoma Myeloma Leuk
Clinical lymphoma, myeloma & leukemia, vol 20, iss 7
Clinical lymphoma, myeloma & leukemia, vol 20, iss 7
Introduction Everolimus and bendamustine both have single-agent activity against lymphoid hematologic malignancies. We examined this combination in a group of heavily pretreated patients with non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and mul
Autor:
Yu Yagi, Eriko Nakashima, Motohiko Ikeda, Yoshimichi Tachikawa, Eriko Fujioka, Takamitsu Matsushima, Hayato Utsunomiya, Youko Suehiro, Tatsuro Goto, Akiko Takamatsu, Hiroshi Takatsuki, Hirofumi Ohno, Taisuke Narazaki, Hiroki Muta, Makoto Oyama, Akie Hirata, Mariko Tsuda, Mitsuo Kozuru, Yuji Yufu, Ilseung Choi, Naokuni Uike, Emi Tanaka, Shojiro Haji, Kaname Miyashita, Junichi Kiyasu, Yasuhiro Tsukamoto, Yasuhiro Nakashima
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e445-e453
Background We retrospectively analyzed patients with untreated aggressive adult T-cell leukemia/lymphoma who received the modified EPOCH (mEPOCH) regimen. Patients and Methods Patients received up to 6 mEPOCH cycles. Etoposide (50 mg/m2/day), doxorub
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e165-e170
Background The treatment landscape for multiple myeloma (MM) has progressed significantly, and over the past decade, bortezomib-based induction therapy has been a standard of care. However, the practice of antibacterial prophylaxis during induction t